$3.5M grant to help Inovio further develop mass vaccine device

04/11/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded Inovio Pharmaceuticals a $3.5 million grant to further develop a next-generation DNA vaccine delivery device that can simultaneously administer multiple synthetic vaccines through skin surface electroporation. The device is being co-developed with Chief Scientist Connie Schmaljohn of the Army Medical Research Institute of Infectious Diseases. The goal is to create a device that will allow fast vaccination of U.S. troops and protect the public from pandemic threats.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL